Australian Cannabis Biotech Up 271%

Analysis originally distributed on August 30, 2017 By: Michael Vodicka of Cannabis Stock Trades

Opioid abuse has quickly grown into a major global epidemic.

While opioids can be great for pain relief, the down side is that they are highly addictive. Recent data shows that opioid abuse and addiction is killing tens of thousands of people every year in just the United States.

Overdose deaths caused by prescription opioids have quadrupled since 1999. From 1999 to 2015, more than 183,000 people have died in the U.S. from overdoses related to prescription opioids.

This is an alarming trend that has both patients and health care professionals asking - are we capable of providing a better alternative?

According to a young biotech located Australia the answer is yes - and the solution comes in the form of cannabis.

If this young cannabis biotech is correct, not only will patients benefit, early shareholders will be rewarded with huge gains.

Let's take a look. Continue reading "Australian Cannabis Biotech Up 271%"

Australian Cannabis Biotech Developing Cancer and Epilepsy Drugs

Analysis originally distributed on August 23, 2016 By: Michael Vodicka of Cannabis Stock Trades

MGC Pharmaceuticals (TSX:MXC, OTC:MGCLF) is a young cannabis biotech headquartered in Western Australia that specializes in pharmaceutical product research and development.

MGC

Australian cannabis stocks have been red hot for the last few months.

  • I added Australian-based Cann Group (ASX:CAN) to the members portfolio on July 31 and we're already up 70% in less than three weeks.
  • I added fellow Australian cannabis stock AusCann (OTC:ACNNF) to the member portfolio on June 6 and we're up 55%.

If you want to learn more about our member portfolio click here.

Although the company is incorporated and headquartered in Australia it also has operations in both Israel and Europe.

For example, MGC received two licenses from the Slovenian government to grow, process and trade Cannabis Sativa L (Hemp) and its products, including Cannabidoil (CBD) resin, in Europe.

The company's founders were leaders in Israel's growing medical cannabis industry. Continue reading "Australian Cannabis Biotech Developing Cancer and Epilepsy Drugs"

Cann Group Up 81% In 3 Weeks

Analysis originally distributed on August 16, 2017 By: Michael Vodicka of Cannabis Stock Trades

This week, I want to share AusCann Group Holdings Ltd. (NASDAQ:ACNNF)/ Cann Group (ASX:CAN) with the free newsletter crowd.

This is a stock I rolled out to members two weeks ago as one of our most recent trades. Members will always get the first look at the best ideas and information we have to offer at CST.

Since being added to the CST portfolio, Cann Group has been surging - Cannabis Stock Trades members are up around 75% on this trade.

2nd Australian Cannabis Permit Holder up 99% in 15 Days - More to Come?

Medical cannabis became legal in Australia in November of 2016.

Under the new program, companies interested in entering the industry must apply for and receive a permit from federal regulators to grow and sell cannabis. Continue reading "Cann Group Up 81% In 3 Weeks"

Warren Buffet Would Love This Cannabis Stock

Analysis originally distributed on July 27, 2017 By: Michael Vodicka of Cannabis Stock Trades

In early 2017 Forbes ranked Warren Buffett as the world’s second richest man with a net worth of $72 billion.

Unlike most other billionaires on the list, Buffett didn’t get rich from owning just one company. Berkshire Hathaway Inc. (NYSE:BRK.B) functioned like a giant mutual fund, investing in many companies from different industries all across the economy. That way, if one industry or company struggled, it wouldn’t crush Berkshire’s performance.

At the core, this is a lesson in diversification. Putting all your eggs in one basket can be risky.

That is particularly true in the cannabis sector. It is a super young industry and cannabis stocks can be quite volatile.

I want to share a cannabis stock that Warren Buffett would love. Continue reading "Warren Buffet Would Love This Cannabis Stock"

Cannabis Cancer Stock Up 207% In 2017

Analysis originally distributed on July 19, 2017 By: Michael Vodicka of Cannabis Stock Trades

Cannabis is a proven treatment for cancer patients struggling with the side effects of chemotherapy such as nausea and loss of appetite.

But now, pre clinical research is showing that cannabis could actually be a cancer killer.

A group of scientists recently reported that THC and CBD slowed the growth and even killed certain cancer cells – including breast, brain and liver cancer – when grown in a lab.

Animal studies also suggest that cannabis could be a cancer killer.

A study conducted by Complutense University, one of the oldest and largest universities in Europe located in Madrid, showed that an injection of a synthetic THC eliminated malignant brain tumors in 1/3 of the rats studied while extending the life of another 1/3. Continue reading "Cannabis Cancer Stock Up 207% In 2017"